Emergencies in rheumatology: Giant cell arteritis with visual symptoms, vertebrobasilar insufficiency or other ischaemic complications;Notfall rheumatologie: riesenzellarteriitis mit sehstörungen, vertebrobasilärer oder anderweitiger akuter arterieller insuffizienz

Aktuelle Rheumatologie

Volumn 35, Issue 1, 2010, Pages 43-48

  Wagner, A D ^a   Dejaco, C ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Emergencies; Giant cell arteritis; Ischaemic complications; Vasculitis

Indexed keywords

CORTICOSTEROID; METHOTREXATE;

ANEURYSM; ARTERY OCCLUSION; BIOPSY; BLINDNESS; BRAIN ISCHEMIA; GIANT CELL ARTERITIS; HUMAN; ISCHEMIC OPTIC NEUROPATHY; REVIEW; VERTEBROBASILAR INSUFFICIENCY;

EID: 77749336052     PISSN: 0341051X     EISSN: 14389940     Source Type: Journal    
DOI: 10.1055/s-0029-1243165     Document Type: Review

References (51)

1. Dejaco C, Duftner C, Wipfler E, et al. 18F-Flourodeoxyglucose positron emission tomography inpolymyalgia rheumatica: novel insight into complex pathogenesis but questionable use in predicting relapses. Rheumatology 2007 46 559-560
2. Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002 347 261-271
3. Gran JT, Myklebust G. The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987-94. J Rheumatol 1997 24 1739-1743
4. Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M, et al. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 1999 26 1326-1332
5. Reinhold-Keller E, Zeidler A, Gutfleisch J, et al. Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology 2000 39 1396-1402
6. Weyand CM, Hunder NN, Hicok KC, et al. HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis. Arthritis Rheum 1994 37 514-520
7. Duhaut P, Bosshard S, Calvet A, et al. Giant cell arteritis, Polymyalgia rheumatica, and viral hypotheses: a multicenter, prospective case-control study. Groupe de Recherche sur l'Artérite á Cellules Géantes. J Rheumatol 1999 26 361-369
8. Wagner AD, Gerard H, Fresemann T, et al. Detection of Chlamydia pneumoniae in giant cell vasculitis and correlation with the topographical arrangement of tissue-infiltrating dendritic cells. Arthritis Rheum 2000 43 1543-1551
9. Njau F, Ness T, Wittkop U, et al. No correlation between giant cell arteritis and Chlamydia pneumoniae infection: investigation of 189 patients by standard and improved PCR methods. J Clin Microbiol 2009 47 1899-1901
10. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003 139 505-515
11. Duftner C, Dejaco C, Schirmer M. [Polymyalgia rheumatica]. Internist 2009 50 51-57
12. Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998 125 509-520 (Pubitemid 28236919)
13. Bogousslavsky J, Deruaz JP, Regli F. Bilateral obstruction of internal carotid artery from giant-cell arteritis and massive infarction limited to the vertebrobasilar area. Eur Neurol 1985 24 57-61
14. Doyle L, McWilliam L, Hasleton PS. Giant cell arteritis with pulmonary involvement. Br J Dis Chest 1988 82 88-92
15. Pfadenhauer K, Esser M, Weber H, et al. [Vertebrobasilar ischemia as a complication of temporal arteritis. Results of a prospective, clinical, ultrasonographic study]. Nervenarzt 2005 76 954-959
16. Geiger J, Uhl M, Peter HH, et al. 3-T MRI detects inflammatory stenosis of the vertebral artery in giant cell arteritis. Clin Rheumatol 2008 27 663-666
17. Lotery A, Best J, Houston S. Occult giant cell (temporal) arteritis presenting with bilateral sixth and unilateral fourth nerve palsies. Eye 1998 12 1014-1016
18. Freitag FG, Diamond S, Solomon GD. Reversible multiple cranial nerve palsies in temporal (giant cell) arteritis with normal sedimentation rate: report of a case. J Am Osteopath Assoc 1988 88 381-383
19. Bruce BB, Biousse V, Newman NJ. Third nerve palsies. Semin Neurol 2007 27 257-268
20. Pfadenhauer K, Roesler A, Golling A. The involvement of the peripheral nervous system in biopsy proven active giant cell arteritis. J Neurol 2007 254 751-755
21. Burton EA, Winer JB, Barber PC. Giant cell arteritis of the cervical radicular arteries presenting with diaphragmatic weakness. J Neurol Neurosurg Psychiatry 1999 67 223-226
22. Duftner C, Seiler R, Dejaco C, et al. Increasing evidence for immune-mediated processes and new therapeutic approaches in abdominal aortic aneurysms a review. Ann N Y Acad Sci 2006 1085 331-338
23. Schirmer M, Duftner C, Seiler R, et al. Abdominal aortic aneurysms: an underestimated type of immune-mediated large vessel arteritis? Curr Opin Rheumatol 2006 18 48-53
24. Liu G, Shupak R, Chiu KY. Aortic dissection in giant cell arteritis. Semin Arthritis Rheum 1995 25 160-171
25. Marie I, Proux A, Duhaut P, et al. Long-term follow-up of aortic involvement in giant cell arteritis: a series of 48 patients. Medicine 2009 88 182-192
26. García-Martínez A, Hernández-Rodríguez J, Arguis P, et al. Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum 2008 59 422-430
27. Nesi G, Anichini C, Pedemonte E, et al. Giant cell arteritis presenting with annuloaortic ectasia. Chest 2002 121 1365-1367
28. Willi N, Nikolaidis D, Gloor D, et al. Instabile Angina pectoris eine mögliche Manifestation der (temporalen) Riesenzellarteriitis. Schweiz Med Forum 2005 5 178-180
29. Godoy P, De Almeida Araújo S, et al. Coronary giant cell arteritis and acute myocardial infarction. Arq Bras Cardiol 2007 88 81-84
30. Ninet JP, Bachet P, Dumontet CM, et al. Subclavian and axillary involvement in temporal arteritis and polymyalgia rheumatica Am J Med 1990 88 13-20
31. Michel BA, Arend WP, Hunder GG. Clinical differentiation between giant cell (temporal) arteritis and Takayasu's arteritis. J Rheumatol 1996 23 106-111
32. Brack A, Martinez-Taboada V, Stanson A, et al. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 1999 42 311-317
33. Brodmann M, Dorr A, Hafner F, et al. Tongue necrosis as first symptom of giant cell arteritis (GCA). Clin Rheumatol 2009 28 (Suppl 1) S47-S49
34. Kahle. Vaskuläre Notfälle in der Dermatologie. Hautarzt 2006 57 202-206
35. Crow RW, Katz BJ, Warner JE, et al. Giant cell arteritis and mortality. J Gerontol A Biol Sci Med Sci 2009 64 365-369
36. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990 33 1122-1128
37. Young BR, Cook BE Jr, Bartley GB, et al. Initiation of glucocorticoid therapy: before and after temporal artery biopsy. Mayo Clin Proc 2004 79 483-491
38. Dejaco C, Seifert T, Duftner C, et al. [Diagnosis and therapy of neurological manifestations of inflammatory rheumatic diseases]. Z Rheumatol 2008 67 386-396
39. Narváez J, Narváez JA, Nolla JM, et al. Giant cell arteritis and polymyalgia rheumatica: usefulness of vascular magnetic resonance imaging studies in the diagnosis of aortitis. Rheumatology 2005 44 479-483
40. Bley TA, Uhl M, Venhoff N, et al. 3-T MRI reveals cranial and thoracic inflammatory changes in giant cell arteritis. Clin Rheumatol 2007 26 448-450
41. Blockmans D, de Ceuninck L, et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 2006 55 131-137
42. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR Recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009 68 318-323
43. Wipfler-Freissmuth E, Loock J, Moosig F, et al. [Current therapeutic options for giant cell arteritis]. Z Rheumatol 2009 68 132-136
44. Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006 54 3310-3318
45. Dejaco C, Wipfler-Freimuth E, Duftner C, et al. Möglichkeiten der Krankheitsaktivitätsmessung bei Vaskulitiden im klinischen Alltag. Aktuel Rheumatol 2009 34 180-185
46. Schmidt WA, Gromnica-Ihle E, Caspary L, et al. Polymyalgia rheumatica und Riesenzellarteriitis (Arteriitis temporalis). In:, Dierkesmann R, Fleig WE, Heidrich H, etal., Hrsg Rationelle Diagnostik und Therapie in der Inneren Medizin: Leitlinien. Mnchen/Jena Elsevier, Urban & Fischer 2006
47. Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlledtrial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002 46 1309-1318
48. Jover JA, Hernandez-Garcia C, Morado IC, et al. Combined treatment of giant cell arteritis with methotrexate and prednisolone: a randomised, double blind, placebo-controlled trial. Annals Int Med 2001 134 106-114
49. Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta-analysis. Arthritis Rheum 2007 56 2789-2797
50. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis. Ann Intern Med 2007 146 621-630
51. Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, et al. A double-blind placebo-controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008 67 625-630